Navigation Links
Mindray's DC-3 Color Ultrasound Gains U.S. FDA 510(k) Clearance

SHENZHEN, China, June 6 /Xinhua-PRNewswire/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced it has received 510(k) clearance from the United States Food and Drug Administration ("FDA") for its DC-3 color ultrasound imaging system. The clearance comes in addition to China State Food and Drug Administration ("SFDA") approval and CE Mark granted earlier this year for the sale of the DC-3 in Chinese and European markets, respectively.

"The compact DC-3 combines outstanding 2D imaging and exceptional color Doppler performance," said Mr. Li Xiting, Mindray's president and co-chief executive officer. "With a superior price-to-performance ratio, we are confident that this versatile product will meet the diverse needs and requirements of hospitals, doctors' offices and veterinary clinics around the world."

The DC-3 color ultrasound imaging system is designed to have extensive applications in abdominal, OB/GYN, endovaginal, cardiac, small parts and pediatric markets. The product is ideally suited for U.S. hospitals, doctors' offices and veterinary clinics seeking to replace black and white ultrasound imaging systems. The DC-3 is tailored to expand Mindray's customer base in low-end markets and complements the company's FDA-approved DC-6 and portable M5 ultrasound imaging systems, which are targeted for middle and high-end markets and received FDA 510(k) clearance in September, 2006 and March, 2008, respectively. The company currently offers over 10 medical imaging products of which five have received FDA 510(k) clearance.

Mindray has to date received FDA 510(k) clearance for a total of 16 products, covering patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems.

About Mindray

Mindray Medical International Limited is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has sales and service offices internationally in Amsterdam, Istanbul, London, Mexico City, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver. For more information, please visit .

For investor inquiries please contact:

In China:

Susan Du

Mindray Medical International Limited

Tel: +86-755-2658-2518


Justin Knapp

Ogilvy Public Relations Worldwide, Beijing

Tel: +86-10-8520-6556


In the United States:

Jeremy Bridgman

Ogilvy Public Relations Worldwide, New York

Tel: +1-212-880-5363

SOURCE Mindray Medical International Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wal-Mart Expands $4 Prescription List in Colorado
2. Baxa Corporation Named Finalist for Third Year as a Best Company to Work For in Colorado
3. Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th
4. Family history of colorectal cancer linked with reduced risk of cancer recurrence
5. Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts
6. Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider
7. Sundays AIDS Walk Boston at the Esplanade Gets Tribute from Cyndi Lauper at True Colors Concert Tour Launch Rehearsal
8. USC study finds sex, age and ethnicity assciated with colorectal cancer survival
9. TV Commercials Color Gender Choices for Careers
10. Can pathological techniques help identify primary colorectal signet ring cell carcinoma?
11. New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
Post Your Comments:
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: